Brief: Pharmaessentia Announces Japan Approval Of High-Dose Dosing Regimen For Besremi
02/03/2026 19:08
March 3 (Reuters) - PharmaEssentia Corp 6446.TW: PHARMAESSENTIA ANNOUNCES JAPAN APPROVAL OF HIGH-DOSE DOSING REGIMEN FOR BESREMI® Source text: ID:nBw2504Mta Further company coverage: 6446.TW ((Reuters.Briefs@thomsonreuters.com;))
Recent news on PHARMAESSENTIA
See all newsBrief: PharmaEssentia Announces Taiwan Approval Of BESREMi For Essential Thrombocythemia
Brief: Pharmaessentia Says Jan-Mar Net Profit T$2.15 Bln
Brief: Pharmaessentia Says To Buy 100% Forus Therapeutics For C$50 Mln
Brief: Pharmaessentia Signs Agreement For New Manufacturing Facility In Puerto Rico
Brief: Pharmaessentia Announces Japan Approval Of High-Dose Dosing Regimen For Besremi